Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

NCT02872025 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Intraductal, Noninfiltrating

Interventions

DRUG: Pembrolizumab
BIOLOGICAL: Intralesional mRNA 2752

Sponsor

Laura Esserman

Collaborators

[object Object]
[object Object]